Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on Hemodialysis in the Russian Federation

Completed

Conditions: Secondary Hyperparathyroidism

Registration Number: NCT01401478

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Brief Summary: Eighty-six eligible participants with secondary hyperparathyroidism will be enrolled at thirteen sites in Russia. Planned therapy will be six months. Participants with Stage 5 Chronic Kidney Disease and with hyperparathyroidism on hemodialysis will be included into the study. Ability of Zemplar, (paricalcitol) to lower intact Parathyroid Hormone level will be assessed during the study.

Detailed Description: Eighty-six eligible participants with secondary hyperparathyroidism will be enrolled at thirteen sites in Russia. Study drug will be administered per local prescribing guidelines. Planned therapy is six months. Intact Parathyroid Hormone will be measured at the Screening visit. All participants who meet the inclusion criteria and fail to meet the exclusion criteria will be included in the study.

Adverse events will be monitored throughout the observation period (and up to 30 days after the last dose of Zemplar).

Ability of Zemplar to lower intact Parathyroid Hormone level will be assessed throughout the study. Proportion of participants with the level of intact Parathyroid Hormone 150 - 300 pg/mL was stated as primary endpoint. Calcium and Phosphorus elevation will be also measured throughout the study.

The selected population is representative in relation to those who will take Zemplar in routine practice. Participants with contraindications to Zemplar therapy (as per the local label) will not be included in the study.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 86

Inclusion Criteria

Age 18-65 years
Chronic Kidney Disease stage 5 receiving hemodialysis
Authorization (Consent) for Use/Disclosure of Data signed by the patient
Planned prescription of Zemplar treatment due to fair clinical need and irrespectively of the participation in the current program according to the local label within 2 weeks after screening into the program
Screening intact Parathyroid Hormone level (measured not earlier than 1 month before first dose of Zemplar) between 300 and 900 pg/mL

Exclusion Criteria

Contraindications to Zemplar as indicated in approved label, including but not limited to hypersensitivity, hypervitaminosis D (serum D3 level above 32 ng/mL), concomitant use of vitamin D or phosphates, lactation period, pregnancy
Any experimental drug within the period of 30 days before the inclusion into the program
Screening Ca x P > 65 mg˄2/dL˄2
Screening normalized serum total calcium > 10.2 mg/dL
Necessity for calcitonin maintenance oral or intravenous glucocorticoids, or other drugs that could have affected calcium or bone metabolism, other than females on stable estrogen and/or progestin therapy

Study & Design

Study Type: OBSERVATIONAL

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The Percentage of Participants Who Reached a Target Level of Intact Parathyroid Hormone (iPTH) (150-300 pg/mL) Post-baseline at Least Once During the Study	6 months	The percentage of participants who had a post-baseline intact parathyroid hormone (iPTH) level in the range of 150 to 300 pg/mL at least once during the study was recorded.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants Who Reached the Kidney Disease Improving Global Outcomes Target Level of Intact Parathyroid Hormone (iPTH) at Least Once During the Study	6 months	The percentage of participants who reached the Kidney Disease Improving Global Outcomes target level of intact parathyroid hormone (iPTH) (defined as achievement of iPTH level 2 to 9 times the upper limit of normal) at least once during the study was recorded.
Percentage of Participants Who Developed Elevated Normalized Total Calcium (> 11.2 mg/dL) at Each Visit Post-baseline During the Study	6 months	The percentage of participants who developed elevated normalized total calcium (\> 11.2 mg/dL) at each visit post-baseline during the study was recorded.
Percentage of Participants Who Developed Elevated Calcium (Ca) x Phosphate (P) (> 75 mg˄2/dL˄2) Levels at Each Visit Post-baseline During the Study	6 months	The percentage of participants who developed elevated calcium (Ca) x phosphate (P) (\> 75 mg˄2/dL˄2) levels at each visit post-baseline during the study was recorded.
Percentage of Participants Who Developed Elevated Normalized Total Calcium (> 11.2 mg/dL) at Least Once Post-baseline During the Study	6 months	The percentage of participants who developed elevated normalized total calcium (\> 11.2 mg/dL) at least once post-baseline during the study was recorded.
Percentage of Participants Who Reached the Kidney Disease Improving Global Outcomes Target Level of Intact Parathyroid Hormone (iPTH) at Each Visit During the Study	6 months	The percentage of participants who reached the Kidney Disease Improving Global Outcomes target level of intact parathyroid hormone (iPTH) (defined as the achievement of iPTH level 2 to 9 times the upper limit of normal) at each visit during the study was recorded.
Percentage of Participants Who Developed Elevated Calcium (Ca) x Phosphate (P) (> 75 mg˄2/dL˄2) Levels at Least Once Post-baseline During the Study	6 months	The percentage of participants who developed elevated calcium (Ca) x phosphate (P) (\> 75 mg˄2/dL˄2) levels at least once post-baseline during the study was recorded.
Percentage of Participants Who Developed Hypercalcemia and Hyperphosphatemia Leading to Study Termination	6 months	The percentage of participants who developed hypercalcemia (too much calcium in the blood) and hyperphosphatemia (too much phosphate in the blood) leading to study termination was recorded. Hypercalcemia was defined as calcium level greater than 11.2 mg/dL for more than 8 weeks, and hyperphosphatemia was defined as phosphate level greater than 6.5 mg/dL for more than 8 weeks.

Trial Locations

Locations (13): Site Reference ID/Investigator# 58347
🇷🇺
Chelyabinsk, Russian Federation
Site Reference ID/Investigator# 57348
🇷🇺
Almetyevsk, Russian Federation
Site Reference ID/Investigator# 67404
🇷🇺
Iakutsk, Russian Federation
Site Reference ID/Investigator# 57344
🇷🇺
Irkutsk, Russian Federation
Site Reference ID/Investigator# 57347
🇷🇺
Cheboksary, Russian Federation
Site Reference ID/Investigator# 57346
🇷🇺
Kazan, Russian Federation
Site Reference ID/Investigator# 57342
🇷🇺
Novosibirsk, Russian Federation
Site Reference ID/Investigator# 58356
🇷🇺
Moscow, Russian Federation
Site Reference ID/Investigator# 57363
🇷🇺
St. Petersburg, Russian Federation
Site Reference ID/Investigator# 69688
🇷🇺
Ulan-Ude, Russian Federation
Site Reference ID/Investigator# 58348
🇷🇺
Moscow, Russian Federation
Site Reference ID/Investigator# 57364
🇷🇺
Orenburg, Russian Federation
Site Reference ID/Investigator# 69687
🇷🇺
Samara, Russian Federation